Citigroup Maintains Buy on Longboard Pharmaceuticals, Lowers Price Target to $17
Citigroup analyst Neena Bitritto-Garg maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and lowers the price target from $24 to $17.
Earnings Scheduled For March 2, 2023
Companies Reporting Before The Bell
• argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus shell and protrusion virus-like particle platform.
Carnival Surges Over 12%, Here’s 75 Biggest Movers From Friday
Gainers
USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Schenker and USA Truck announced plans to combine and create premier North American transportation solutions provider.
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that moved stocks during the week.
Longboard Pharmaceuticals Q3 EPS $(0.38) Up From $(0.66) YoY
Longboard Pharmaceuticals (NASDAQ:LBPH) reported quarterly losses of $(0.38) per share. This is a 42.42 percent increase over losses of $(0.66) per share from the same period last year.
Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion Of Phase 1 Clinical Trial In Healthy Volunteers, Plans To Initiate Phase 1b/2a Clinical Trial
Favorable safety, tolerability, pharmacokinetics and pharmacodynamics were observed
Central 5-HT2c receptor engagement demonstrated by dose- and exposure-dependent increases of prolactin
Company